Foghorn Therapeutics Inc. (FHTX) Misses Q2 EPS by 9c

Foghorn Therapeutics Inc. (NASDAQ: FHTX) reported Q2 EPS of ($0.66), $0.09 worse than the analyst estimate of ($0.57). Revenue for the quarter came in at $4.49 million versus the consensus estimate of $8.69 million.

For earnings history and earnings-related data on Foghorn Therapeutics Inc. (FHTX) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• KB Home (KBH) Misses Q2 EPS by 2c; Offers Outlook